13/09/2017 22:32:26

CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer

SANTA CLARA, Calif., 2017-09-13 23:32 CEST (GLOBE NEWSWIRE) --

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that their integrated oncology platform has facilitated the preclinical development of a HERA-GITRL immunotherapeutic from Apogenix. HERA-GITRL is an immunotherapy showing antitumor activity in Non-Small Cell Lung Cancer (NSCLC) and Head and Neck Cancer.

The data derived from studies using CrownBio’s portfolio were first presented by Apogenix in an oral presentation at the AACR 2017 Annual Meeting. These data showed the immunotherapy’s potential clinical utility and demonstrated the benefits of using CrownBio’s platform in preclinical efficacy testing.

“CrownBio’s integrated oncology platform confirmed our agent’s efficacy in NSCLC and head and neck cancers,” said Dr. Mauricio Redondo Müller, Director, Preclinical Development at Apogenix. “The scientific expertise, predictive tools, and well-validated models CrownBio provides gave us the data we needed to progress our HERA-GITRL immunotherapy to the next stage.”

“It is our mission to deliver innovative technologies so that companies like Apogenix can leverage and accelerate their research,” said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development. “Our scientific oncology platform uniquely enhances preclinical immunotherapy development and will continue to deliver valuable insights that drive new discoveries in this area.”

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

About Apogenix

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 100 million euros in financing rounds, public grants, and upfront payments from licensing agreements. The company is based in Heidelberg, Germany.

         Media Enquiries:

         

         Jody Barbeau

         

         Crown Bioscience Inc. marketing@crownbio.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Nov
ALMB
Når man dagligt læser indlæg fra Alpehuen, Mackkeith, Malurt, EMEA (MENA), Powertrade som via en flo..
30
17 Nov
PNDORA
Om nogen, har jeg ikke meget tilovers for GW, men jeg har tilladt mig at anmelde dit indlæg. Nu må i..
29
16 Nov
NOVO-B
Og Goodwrench, Baronen og marc55
25
20 Nov
I:SP500
God aften   Gå lige ind under Conference Board i USA og læs, at de ledende indikatorer steg med hele..
23
17 Nov
OMXC20
  Her kommer en kort gennemgang og forklaring på, hvorfor aktietilbagekøb både kan være rigtig godt ..
23
20 Nov
VWS
Roland, nu må du simpelthen stoppe. Det her er simpelthen for ynkeligt, hvordan kan du være så selvi..
21
18 Nov
I:NDX
Der er efterhånden alt for få på EI, der bruger hovedparten af deres tid på at tjene penge på aktier..
18
19 Nov
PNDORA
Hvad skal vi med millionærklubben når vi har roland333 
17
18:27
PNDORA
Hej Roland.   Dem du prøver at råde om aktiehandel, fortjener at vide hvilken tåbe, der prøver at rå..
16
16 Nov
VWS
Lavede en kæmpe fodfejl med Vestas. Købte i den private frie pot 1200 stk med gak 402,8 fordi jeg..
15

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

21/11/2017 15:35:27
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Alliance Trust PLC : Net Asset Value(s)

21/11/2017 13:37:22
ALLIANCE TRUST PLC                                    At the close of business on Monday 20 November 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.0p -       including income, 787.7p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inc..

Admiral Group PLC : Holding(s) in Company

21/11/2017 10:20:10
TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma
2
Novea Inc.'s Captive Insurance Subsidiary Jacana Insurance Engages Madison RE I.I. to Provide Reinsurance for Jacana Warranty Offerings
3
ICTV Brands Reports 3Q17 Financial Results
4
Aryaka to Present Global SD-WAN Use Cases and Enterprise Deployment Stories at 6th Annual CIO Leaders Singapore Summit
5
Zomedica Pharmaceuticals Corp. Registration Statement Declared Effective by U.S. Securities and Exchange Commission

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 November 2017 20:55:01
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171108.1 - EUROWEB3 - 2017-11-21 21:55:01 - 2017-11-21 20:55:01 - 1000 - Website: OKAY